Ann: Final Sofdra Labelling Discussions with FDA, page-202

OK so we are a market cap of 520M.

We will see more appreciation - pre-approval (30% appreciation)?
I note the analyst report, had on average a 30% appreication (past 30 days) pre-approval.
Currently we are at 21% (past 30 days).
Notice the market cap average is about 1155M before approval,
however note this is only 6 companies sample size, you can see the great variance
probably very different companies with all different pipelines...
some have 260M market cap on approval and others have 2460M before FDA approval

I dunno I don't see much more appreciation, before approval, Euroz had us valued at 33c - interesting it is there nowish.


Where should/will we be post-approval? ~(40c)
I am not trying to downramp etc, or piss anyone off, but realistically
I reckon we may a small spike and then settle into the 40s (even late 30s) post approval, until sales come (assuming in 3rd quarter)

But then again, the market is fwd looking, who knows, we may double to 1000M (66c) upon approval.

Just speculations, etc,